Global biotechnology company NodThera is developing a new class of potent and selective small-molecule NLRP3 inhibitors for the treatment of diseases driven by chronic inflammation, such as ...
Co. Ltd. and Viva Star Biosciences (US) Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, ...
Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical ...
The NLRP3 inflammasome is a key inflammation driver linked to central nervous system (CNS) disorders, metabolic diseases, and aging-related conditions. JOTROL, Jupiter’s flagship product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback